Solid-Phase Synthesis of Peptidomimetic Inhibitors for the Hepatitis C Virus NS3 Protease
The Journal of Organic Chemistry2001Vol. 66(14), pp. 4743–4751
Citations Over TimeTop 10% of 2001 papers
Marc‐André Poupart, Dale R. Cameron, Catherine Chabot, Élise Ghiro, Nathalie Goudreau, Sylvie Goulet, Martin Poirier, Youla S. Tsantrizos
Abstract
The NS3 serine protease enzyme of the hepatitis C virus (HCV) is essential for viral replication. Short peptides mimicking the N-terminal substrate cleavage products of the NS3 protease are known to act as weak inhibitors of the enzyme and have been used as templates for the design of peptidomimetic inhibitors. Automated solid-phase synthesis of a small library of compounds based on such a peptidomimetic scaffold has led to the identification of potent and highly selective inhibitors of the NS3 protease enzyme.
Related Papers
- → Single-point mutations of hepatitis C virus NS3 that impair p53 interaction and anti-apoptotic activity of NS3(2005)28 cited
- → In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease(2006)18 cited
- → Solid-Phase Synthesis of Peptidomimetic Inhibitors for the Hepatitis C Virus NS3 Protease(2001)59 cited
- → Site‐directed mutagenesis of the tick‐borne encephalitis virus NS3 gene reveals the putative serine protease domain of the NS3 protein(1993)14 cited
- → Research advances in the methods for monitoring hepatitis C virus NS3/4A protease activity(2012)